Charakida A, Dadzie O, Teixeira F, Charakida M, Evangelou G, Chu A C
Department of Dermatology, Hammersmith Hospital Campus, Imperial College, London, W12 0HS, UK.
Expert Opin Pharmacother. 2006 Apr;7(5):597-606. doi: 10.1517/14656566.7.5.597.
The two-compound product calcipotriol/betamethasone dipropionate is arising as a first-line treatment for mild-to-moderate plaque psoriasis. Its beneficial action is attributed to the synergistic effect of its components on keratinocyte proliferation and differentiation, and on inflammation. The good tolerability of the two-compound product is thought to be due to the anti-inflammatory effect of betamethasone. Evidence from short-term (4-12 weeks) and long-term use (> 1 year) has shown a good safety profile. Areas such as the face or skin folds, which are sensitive to the components of the combination, should be avoided. Finally, it is unsuitable for use in unstable psoriasis, in which potent steroids may lead to an increased inflammatory response.
